Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 9 trials

Late-Stage Pipeline

22%

2 trials in Phase 3/4

Results Transparency

0 of 0 completed trials have results

Key Signals

7 recruiting

Enrollment Performance

Analytics

Phase 1

4(44.4%)

Phase 2

3(33.3%)

Phase 3

2(22.2%)

9Total

Phase 1(4)

Phase 2(3)

Phase 3(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT07522099Phase 2Recruiting

Chinese Adults With Kidney Disease

Role: lead

NCT07428499Phase 3Recruiting

Phase 3 Extension Study of ADX-324 in Participants With Hereditary Angioedema (HAE)

Role: lead

NCT05691361Phase 1Active Not Recruiting

Safety, Tolerability, PK, PD of ADX-324 in Healthy Volunteers and Hereditary Angioedema Patients

Role: lead

NCT06990269Phase 2Recruiting

Phase 2 Study of ADX-038 in Participants With Geographic Atrophy

Role: lead

NCT06205628Phase 1Active Not Recruiting

Safety, Tolerability, PK and PD of ADX-850 in Participants With Hypertension

Role: lead

NCT05876312Phase 1Recruiting

Safety, Tolerability, PK and PD of ADX-038 in Healthy Participants and Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients

Role: lead

NCT06960213Phase 3Recruiting

STOP-HAE: A Phase 3 Study of ADX-324 in HAE

Role: lead

NCT06989359Phase 2Recruiting

Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease

Role: lead

NCT07081503Phase 1Recruiting

Phase 1 Study of ADX-626 in Healthy Participants

Role: lead

All 9 trials loaded